| ObjectiveTo evaluate the validity and security of ginkgo biloba combined with aspirin in thetreatment and secondary prevention for the acute ischemic stroke patients through theclinical random control test.Method80cases with acute ischemic stroke were selected at the in-patient,Department ofNeurology,the First Affiliated Hospital of Soochow University,from October2011toDecember2013.All of them were in five days from onset. The patients were enrolled anddivided randomly into ginkgo biloba test group and aspirin control roup.Clinical data indetail was collected among all cases,including gender,age, anamnesis,(hypertension,diabetes, dislipidemia,heart disease,ischemic stroke and so on), history oftreatment,hypersensitivity,history of smoking and drinking.All patients underwent ECG,blood test, urinalysis, dejecta analysis, blood chemistry test, image test of head. HIHSSand MMSE values were underwent on the2week,4week,12week and24week for thepatient. The rate of the blood platelet aggregation were tested on the onset,2week and12week. The ESSEN value were underwent and the rates of ischemic stroke recrudescencewere accorded for the two group. Function of hepatia and kidney,level of lipidemia weretested on2week,12week,24week for all the patients. SPSS13.0software was used forstatistical analysis.Result1.1.The treatment group and the control group all included40patients according tothe method of the treatment.There are39patients finishing the study for the group of theginkgo biloba combined with aspirin,which include26males and14females, aged (65.55±6.10).39patients for the aspirin control group finished the study,which included28males and11females,aged(68．65±7．15). The infarction part of the brain：40cases forbasal ganglia infarction,8cases for brain stem infarction,20cases for the brain lobeinfarction,10cases for multiple infarction.68cases combined with hypertension,45casescombined with diabetes.13cases combined with coronary heart disease.There is nostatistical difference for gender,age,incorporative diseases for the two groups(p>0.05).Onepatient of the treatment group was excluded for the cancer of lung.Ischmic strokehappened again for one patient of the control group on16weeks.2. The baseline NIHSS values for the ginkgo biloba treatment group was12.81±4.81for the acute ischemic stroke patient, and13.01±2.08for the aspirin control group.There is no statistical difference significantly for the two group(P>0.05). The NIHSSvalue for the ginkgo biloba group were7.57±2.23on2week，and8.94±2.81for thecontrol group. The difference for the two group is statistical significant(p<0.05). But on the4week,12week and24week the differences of the NIHSS value for the two groups areno-statistical significance.3. The baseline MMSE values for the ginkgo biloba treatment group was15.7±3.3,and15.5±3.1for the aspirin control group. There is no statistical differencesignificantly for the two group(P>0.05). The MMSE values for the ginkgo biloba groupwere15.9±3.2,15.8±3.3and16.8±4.3on2week,4week and12weeks separately,soon as16.5±4.6,17.6±4.5and17.3±4.2for the control group. The differences for the twogroup is no-statistical significance(p>0.05).While The MMSE value for the ginkgo bilobagroup were24.5±4.6on24week,so on as20.4±4.3for the control group. The differencefor the two group is statistical significant(p<0.05).4. The baseline rate differences of blood platelet aggregation for the ginkgo bilobatreatment group and for the aspirin control group,are not statistical significantly(P>0.05).The rate of blood platelet aggregation which AA reduced for the ginkgo biloba group were0.374±0.263and0.325±0.239on2week and12weeks separately,so on as0.374±0.263and0.501±0.260for the control group. The differences for the twogroup is no-statistical significance(p>0.05).While the difference is statistical significant for rate of blood platelet aggregation whicn PAF reduced(p<0.05). for the ginkgo biloba groupthe rate is0.452±0.220and0.332±0.215,while0.416±0.262and0.477±0.198separatelyfor the control group.5. The baseline ESSEN values for the ginkgo biloba treatment group was3.6±1.1,and3.5±1.2for the aspirin control group. There is no statistical difference significantly forthe two group(P>0.05). The rate of ischemic stroke recrudescence is0%for the treatmentgroup,0.25%for the control group in24weeks. The difference is significantstatistically (p<0.05).Conclusion1.The NIHSS value of group ginkgo biloba combined with aspirin is lower than thecontrol group significantly in the acute ischemic stroke patients. The result review thatginkgo biloba is benefit for the ischemic stroke patients in acute period of the disease.But there is no significant difference between the test group and the control group in thelong term.2.The MMSE value of the test group is higher than the control group significantly in24weeks,which reveal that ginkgo could improve the cognitive function in the ischemicstroke patients, and be good for VD.3.The gingko biloba could inhibit the planet aggregation through blocking on the PAFand ADP pathway in vivo,which is important for the secondary prevention of the ischemiccerebrovascular diseases.4.The recurrence rate of the test group is lower than the control group in24weeks,which show that ginkgo biloba could reduce the recurrence of the ischemic strokeand be propitious to secondary prevention. |
PDF Full Text Request